Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
US10647771B2 · kind B2 · utility
1Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2016 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Jan 20, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4704
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.